182 related articles for article (PubMed ID: 19512981)
1. Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study.
Coryell W; Rickels H
J Clin Psychopharmacol; 2009 Apr; 29(2):174-8. PubMed ID: 19512981
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
3. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Stahl SM; Gergel I; Li D
J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
[TBL] [Abstract][Full Text] [Related]
4. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo.
Bandelow B; Stein DJ; Dolberg OT; Andersen HF; Baldwin DS
Pharmacopsychiatry; 2007 Jul; 40(4):152-6. PubMed ID: 17694478
[TBL] [Abstract][Full Text] [Related]
5. Onset of spontaneous panic attacks: a prospective study of risk factors.
Coryell W; Dindo L; Fyer A; Pine DS
Psychosom Med; 2006; 68(5):754-7. PubMed ID: 17012529
[TBL] [Abstract][Full Text] [Related]
6. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine.
Mortimore C; Anderson IM
Psychopharmacology (Berl); 2000 Apr; 149(3):251-8. PubMed ID: 10823406
[TBL] [Abstract][Full Text] [Related]
7. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects.
Papp LA; Martinez JM; Klein DF; Coplan JD; Norman RG; Cole R; de Jesus MJ; Ross D; Goetz R; Gorman JM
Am J Psychiatry; 1997 Nov; 154(11):1557-65. PubMed ID: 9356564
[TBL] [Abstract][Full Text] [Related]
8. Anxiety responses to CO2 inhalation in subjects at high-risk for panic disorder.
Coryell W; Pine D; Fyer A; Klein D
J Affect Disord; 2006 May; 92(1):63-70. PubMed ID: 16527360
[TBL] [Abstract][Full Text] [Related]
9. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
10. Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo.
Kreiter D; Drukker M; Mujagic Z; Vork L; Rutten BPF; van Os J; Masclee AAM; Kruimel JW; Leue C
J Psychosom Res; 2021 Feb; 141():110351. PubMed ID: 33412422
[TBL] [Abstract][Full Text] [Related]
11. Effects of 35% carbon dioxide (CO
Kellner M; Muhtz C; Nowack S; Leichsenring I; Wiedemann K; Yassouridis A
J Psychiatr Res; 2018 Jan; 96():260-264. PubMed ID: 29128558
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
13. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
[TBL] [Abstract][Full Text] [Related]
14. Temporal stability of multiple response systems to 7.5% carbon dioxide challenge.
Roberson-Nay R; Gorlin EI; Beadel JR; Cash T; Vrana S; Teachman BA
Biol Psychol; 2017 Mar; 124():111-118. PubMed ID: 28163046
[TBL] [Abstract][Full Text] [Related]
15. The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study.
Bertani A; Caldirola D; Bussi R; Bellodi L; Perna G
J Clin Psychopharmacol; 2001 Jun; 21(3):262-7. PubMed ID: 11386488
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Davidson JR; Bose A; Korotzer A; Zheng H
Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
[TBL] [Abstract][Full Text] [Related]
17. The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.
Vork L; Mujagic Z; Drukker M; Keszthelyi D; Conchillo JM; Hesselink MAM; van Os J; Masclee AAM; Leue C; Kruimel JW
Neurogastroenterol Motil; 2019 Jan; 31(1):e13515. PubMed ID: 30460734
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and substance specificity of carbon-dioxide-induced panic.
Papp LA; Klein DF; Martinez J; Schneier F; Cole R; Liebowitz MR; Hollander E; Fyer AJ; Jordan F; Gorman JM
Am J Psychiatry; 1993 Feb; 150(2):250-7. PubMed ID: 8123056
[TBL] [Abstract][Full Text] [Related]
19. Carbon dioxide/oxygen challenge test in panic disorder.
Perna G; Battaglia M; Garberi A; Arancio C; Bertani A; Bellodi L
Psychiatry Res; 1994 May; 52(2):159-71. PubMed ID: 7972572
[TBL] [Abstract][Full Text] [Related]
20. Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study.
Perna G; Bertani A; Gabriele A; Politi E; Bellodi L
J Clin Psychopharmacol; 1997 Jun; 17(3):173-8. PubMed ID: 9169961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
